Rapid Reversion of Loeffler's Endocarditis by Imatinib in Early Stage Clonal Hypereosinophilic Syndrome

References

• Loftier, W. (1936) "Endocarditis parietalis fibroplastica mit bluteosinophilie. Ein eigenartiges Krankheitsbild", Schweiz Med. Wochenschr., 66, 817–820.
   Google Scholar
• Ommen, S.R., Seward, J.B. and Tajik, A.J. (2000) "Clinical and echocardiographic features of Hypereosinophilic Syndromes", Am. J. CardioL, 86, 110 — 113.
   Web of Science ®Google Scholar
• Schaller, J.L. and Burkland, G.A. (2001) "Rapid and complete control of Idiopathic Hypereosinophilia with Imatinib Mesylate", Medscape Gen. Med., 3, 5–9.
   Google Scholar
• Gleich, G.J., Leiferman, KM., Pardanani, A., Tefferi, A. and Butterfield, J.H. (2002) "Treatment of hypereosinophilic syndrome with imatinib mesilate", Lancet, 359, 1577–1578.
   Google Scholar
• Abboud, C., Jankov, A., Felgar, R., Arbini, A., Rosell, K. and Liesveld, J. (2002) "Idiopathic Hypereosinophilic Syndrome: in vivo response to Imatinib Mesilate, and inhibition of eosinophil progenitors in vitro", Exp. Hematol., 30, suppl. 1: abs. 184.
   Google Scholar
• Ault, P., Cortes, J., Koller, C., Kaled, E.S. and Kantarjian, H. (2002) "Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesilate", Leukemia Res., 26, 881–884.
   PubMed Web of Science ®Google Scholar
• Cortes, J., Ault, P., Koller, C., Thomas, D., Ferrajoli, A., Wierda, W., et al. (2003) "Efficacy of imatinib mesilate in the treatment of idiopathic hypereosinophilic syndrome", Blood, 101, 4714–4716.
   Google Scholar
• Pardanani, A., Ketterling, R.P., Brockman, SR., Flynn, H.C., Paternoster, S.F., Shearer, B.M., et al. (2003) "CHIC2 deletion, a surrogate for FIP IL I-PDGFRA fusion, occurs in systemic masto-cytosis associated with eosinophilia and predict response to imatinib mesilate", Blood, 102, 3093–3096.
   PubMed Web of Science ®Google Scholar
• Vandenberghe, P., Wlodarska, I., Michaux, L., Zachée, P., Boogaerts, M., Vanstraelen, D., et al. (2004) "Clinical and molecular features of FIPILI-PDGFRa ( + ) chronic eosinophilic leukemias. Leukemia, 18, 734–742.
   Google Scholar
• Cools, J., DeAngelo, Di., Gotlib, J., Stover, E.H., Legare, L.D., Cortes, J., et al. (2003) "A tyrosine lcinase created by fusion of the PDGFRA and FIP ILI genes as a therapeutic target of imatinib in Idiopathic Hypereosinophilic Syndrome", N. Engl. J. Med., 348, 1201 — 1214.
   Google Scholar
• Degan, M., Mazzocco, FT., Di Francia, R., Rossi, F.M., Pinto, A. and Gattei, W. (2000) "Normalizing complementary DNA by quantitative reverse transcriptase-polymerase chain reaction of /32-microglobulin: molecular monitoring of minimal residual disease in acute promyelocytic leukemia", Diagn. MoL PathoL, 9, 98–109.
   Google Scholar
• Fauci, AS., Harley, J.B., Roberts, W.C., Ferrans, VT, Gralnick, H.R. and Bjornson, B.H. (1982) "The Idiopathic Hypereosinophilic Sindrome", Ann. Intern. Med., 97, 78–92.
   Web of Science ®Google Scholar
• Bain, B.J. (1996) "Eosinophilic leukemias and the idiopathic hypereosinophilic syndrome", Br. J. HaematoL, 95, 2–9.
   Google Scholar
• Fujii, N., Ikeda, K., Takahashi, N., Kojima, K., Kobayashi, Y., Ashiba, A., et al. (2002) "Multilineage involvement in hypereosi-nophilic syndrome terminating in granulocytic sarcoma and leukaemic transformation with trisomy 8", Br. J. HaematoL, 119, 716 —719.
   Web of Science ®Google Scholar
• Catalano, L., Alfinito, F., Selleri, C., Luciano, L., Fazio, S. and Rotoli, B. (1987) "Sindrome ipereosinofila esitata in leucemia acuta promielocitica". In Attualitci in Ematologia. Atti del XXXI Congresso della Società Italiana di Ematologia. Monduzzi Editore. Bologna, Italy, pp. 83–85.
   Google Scholar
• Bain, B.J. (2000) "Hypereosinophilia", Curr. Opin. HematoL, 7, 21 — 25.
   PubMed Web of Science ®Google Scholar
• Cabrol, C. (1979) "Chromosomal anomaly in eosinophilic leuke-mia", N. Engl. J. Med., 301, 439.
   Google Scholar
• Malbrain, M.L.N.G., Van den Bergh, H. and Zachée, P. (1996) "Further evidence for the clonal nature of the idiopathic hyper-eosinophilic syndrome: complete hematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality", Br. J. HematoL, 92, 176–183.
   PubMed Web of Science ®Google Scholar
• Luciano, L., Catalano, L., Sarrantonio, C., Guerriero, A., Califano, C. and Rotoli, B. (1999) "afFN-induced hematologic and cytoge-netic remission in chronic eosinophilic leukemia with t(1;5)", Haematologica, 84, 651— 653.
   PubMed Web of Science ®Google Scholar
• Pardanani, A., Reeder, T., Porrata, L.F., Li, C.Y., Tazelaar, H.D., Baxter, J., et al. (2003) "Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders", Blood, 101, 3391 — 3397.
   Google Scholar
• Pitini, V., Arrigo, C., Azzarello, D., La Gattuta, G., Amata, C., Righi, M., et al. (2003) "Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcome", Blood, 102, 3456— 3457.
   Google Scholar
• Yuan, Q., Austen, K.F., Friend, D.S., Heidtman, M. and Boyce, J.A. (1997) "Human peripheral blood eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4)-mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1)", J. Exp. Med., 186, 313–323.
   PubMed Web of Science ®Google Scholar
• Cross, N.C.P. and Reiter, A. (2002) "Tyrosine Kinase fusion genes in chronic myeloproliferative diseases", Leukemia, 16, 1207–1212.
   Google Scholar